+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dermatologicals Market by Disease, Type and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 262 Pages
  • January 2022
  • Region: Global
  • Allied Market Research
  • ID: 5561132
The global dermatological market was valued at $19,974.3 million in 2020, and is projected to reach $59,309.3 million by 2030, registering a CAGR of 11.5% from 2021 to 2030.



Dermatological are a class of medicine used to treat patients suffering from skin disorders. These preparations are used to treat conditions such as psoriasis, acne, and rosacea. Different types of dermatological formulations are available in the market, including topical, parenteral, and oral. The treatment for skin diseases are prescribed depending upon the type and severity of symptoms. For instance, psoriasis requires the use of parenteral dermatological preparations for treatment.

The growth of the global dermatological market is majorly driven by alarming increase in prevalence of skin diseases such as acne, atopic dermatitis, psoriasis, and rosacea; rise in government initiatives to spread awareness & promote knowledge about skin disease; surge in number of dermatological drugs manufacturing; surge in expenditure on human healthcare services; and increase in adoption of skin care products. For instance, the American Academy of Dermatology Association aims to develop frontiers of dermatologic care and increase dermatologic services for under-served population. This program further aims to increase consumer understanding about the importance of care delivered by board-certified dermatologists. Moreover, dermatological products are prescribed to patients suffering from COVID-19 and who develop skin diseases such as urticaria, morbilliform rash, and perni-like acral lesions.

Furthermore, rise in number of teenagers and younger population drive the growth of the market. This is attributed to the fact that the teenager population is highly vulnerable to skin diseases such as acne, due to change in hormonal level, which boosts the demand for various dermatological drug therapies for better health outcomes. This factors is expected to notably contribute toward the growth of the global dermatologicals market.

In addition, the development of the pharmaceutical sector is a major factor that drives the global dermatologicals market. Moreover, increase in number of clinical studies significantly contributes toward the market growth. Clinical studies aim to evaluate safety and efficacy of dermatological products. Rise in number of approval of dermatological products acts as a key driving force of the global market. For instance, in December 2021, Amgen, a biopharmaceutical company, announced the Food and Drug administrationn (FDA) approval of Otezla (apremilast), which is recommended for the treatment of patients diagnosed with plaque psoriasis.

Furthermore, rise in funds by governments of various countries and private organizations to develop pharmaceutical manufacturing units are expected to boost the market growth. For instance, in March 2020, the Department of Pharmaceutical, in India, announced the investment scheme of around $1,300 million to strengthen the domestic active pharmaceutical ingredient units and boost the manufacturing of pharmaceutical products. In addition, increase in R&D activities in pharmaceutical industry is anticipated to provide lucrative opportunities for the market expansion.

However, availability of alternative treatment options for acne and other skin diseases hinders the market growth. On the contrary, increase in awareness among population about various treatments available for skin diseases augments the growth of the dermatologicals market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the dermatologicals market.

The global dermatologicals market is segmented into disease, type, route of administrationn, and region. By disease, the market is categorized into acne, dermatitis, psoriasis, skin cancer, rosacea, alopecia, and others. Depending on type, it is fragmented into prescription-based drugs and over-the-counter drugs. On the basis route of administrationn, it is segregated topical administrationn, oral administrationn, and parenteral administrationn. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global dermatologicals market are AbbVie Inc. (Allergan PLC)., Amgen Inc., Galderma, GlaxoSmithKline Plc., Johnson & Johnson Services Inc, Leo Pharma A/S, Novartis AG, Organon & Co (Merck), Pfizer Inc., and Sun Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global dermatologicals market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global dermatologicals market

KEY MARKET SEGMENTS


By Disease

  • Acne
  • Dermatitis
  • Psoriasis
  • Skin Cancer
  • Rosacea
  • Alopecia
  • Other

By Type

  • Prescription-based drugs
  • Over-the-Counter drugs

By Route of administrationn

  • Topical administration
  • Oral administration
  • Parenteral administration

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie Inc. (Allergan PLC).
  • Amgen Inc.
  • Galderma
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Services Inc
  • Leo Pharma A/S
  • Novartis AG
  • Organon & Co (Merck)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited.
Frequently Asked Questions about the Global Dermatologicals Market

What is the estimated value of the Global Dermatologicals Market?

The Global Dermatologicals Market was estimated to be valued at $19974.3 million in 2020.

What is the growth rate of the Global Dermatologicals Market?

The growth rate of the Global Dermatologicals Market is 11.5%, with an estimated value of $59309.3 million by 2030.

What is the forecasted size of the Global Dermatologicals Market?

The Global Dermatologicals Market is estimated to be worth $59309.3 million by 2030.

Who are the key companies in the Global Dermatologicals Market?

Key companies in the Global Dermatologicals Market include AbbVie Inc.(Allergan PLC)., Amgen Inc., Galderma, GlaxoSmithKline Plc., Johnson & Johnson Services Inc, Leo Pharma A/S, Novartis AG, Organon & Co (Merck) and Sun Pharmaceutical Industries Limited.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of skin diseases
3.5.1.2. Increase in number of approval for dermatological products
3.5.1.3. Rise in awareness among individuals regarding skin diseases
3.5.2. Restraint
3.5.2.1. Availability of alternatives for acne treatment
3.5.3. Opportunities
3.5.3.1. Increase in healthcare expenditure
3.5.3.2. Development of pharmaceutical industry
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the dermatologicals market
CHAPTER 4: DERMATOLOGICALS MARKET, BY DISEASE
4.1. Overview
4.1.1. Market size and forecast
4.2. Acne
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Dermatitis
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Psoriasis
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Skin cancer
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Rosacea
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Alopecia
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Others
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
CHAPTER 5: DERMATOLOGICALS MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription-based drugs
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Over-the-counter drugs
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country
CHAPTER 6: DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Topical administration
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. Oral administration
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
6.4. Parenteral administration
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market analysis, by country
CHAPTER 7: DERMATOLOGICALS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America dermatologicals market, by disease
7.2.3. North America dermatologicals market, by type
7.2.4. North America dermatologicals market, by route of administration
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. U.S. dermatologicals market, by disease
7.2.5.1.2. U.S. dermatologicals market, by type
7.2.5.1.3. U.S. dermatologicals market, by route of administration
7.2.5.2. Canada
7.2.5.2.1. Canada dermatologicals market, by disease
7.2.5.2.2. Canada dermatologicals market, by type
7.2.5.2.3. Canada dermatologicals market, by route of administration
7.2.5.3. Mexico
7.2.5.3.1. Mexico dermatologicals market, by disease
7.2.5.3.2. Mexico dermatologicals market, by type
7.2.5.3.3. Mexico dermatologicals market, by route of administration
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe dermatologicals market, by disease
7.3.3. Europe dermatologicals market, by type
7.3.4. Europe dermatologicals market, by route of administration
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Germany dermatologicals market, by disease
7.3.5.1.2. Germany dermatologicals market, by type
7.3.5.1.3. Germany dermatologicals market, by route of administration
7.3.5.2. France
7.3.5.2.1. France dermatologicals market, by disease
7.3.5.2.2. France dermatologicals market, by type
7.3.5.2.3. France dermatologicals market, by route of administration
7.3.5.3. UK
7.3.5.3.1. UK dermatologicals market, by disease
7.3.5.3.2. UK dermatologicals market, by type
7.3.5.3.3. UK dermatologicals market, by route of administration
7.3.5.4. Italy
7.3.5.4.1. Italy dermatologicals market, by disease
7.3.5.4.2. Italy dermatologicals market, by type
7.3.5.4.3. Italy dermatologicals market, by route of administration
7.3.5.5. Spain
7.3.5.5.1. Spain dermatologicals market, by disease
7.3.5.5.2. Spain dermatologicals market, by type
7.3.5.5.3. Spain dermatologicals market, by route of administration
7.3.5.6. Rest of Europe
7.3.5.6.1. Rest of Europe dermatologicals market, by disease
7.3.5.6.2. Rest of Europe dermatologicals market, by type
7.3.5.6.3. Rest of Europe dermatologicals market, by route of administration
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific dermatologicals market, by disease
7.4.3. Asia-Pacific dermatologicals market, by type
7.4.4. Asia-Pacific dermatologicals market, by route of administration
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Japan dermatologicals market, by disease
7.4.5.1.2. Japan dermatologicals market, by type
7.4.5.1.3. Japan dermatologicals market, by route of administration
7.4.5.2. China
7.4.5.2.1. China dermatologicals market, by disease
7.4.5.2.2. China dermatologicals market, by type
7.4.5.2.3. China dermatologicals market, by route of administration
7.4.5.3. Australia
7.4.5.3.1. Australia dermatologicals market, by disease
7.4.5.3.2. Australia dermatologicals market, by type
7.4.5.3.3. Australia dermatologicals market, by route of administration
7.4.5.4. India
7.4.5.4.1. India dermatologicals market, by disease
7.4.5.4.2. India dermatologicals market, by type
7.4.5.4.3. India dermatologicals market, by route of administration
7.4.5.5. South Korea
7.4.5.5.1. South Korea dermatologicals market, by disease
7.4.5.5.2. South Korea dermatologicals market, by type
7.4.5.5.3. South Korea dermatologicals market, by route of administration
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Rest of Asia-Pacific dermatologicals market, by disease
7.4.5.6.2. Rest of Asia-Pacific dermatologicals market, by type
7.4.5.6.3. Rest of Asia-Pacific dermatologicals market, by route of administration
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA dermatologicals market, by disease
7.5.3. LAMEA dermatologicals market, by type
7.5.4. LAMEA dermatologicals market, by route of administration
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Brazil dermatologicals market, by disease
7.5.5.1.2. Brazil dermatologicals market, by type
7.5.5.1.3. Brazil dermatologicals market, by route of administration
7.5.5.2. Saudi Arabia
7.5.5.2.1. Saudi Arabia dermatologicals market, by disease
7.5.5.2.2. Saudi Arabia dermatologicals market, by type
7.5.5.2.3. Saudi Arabia dermatologicals market, by route of administration
7.5.5.3. South Africa
7.5.5.3.1. South Africa dermatologicals market, by disease
7.5.5.3.2. South Africa dermatologicals market, by type
7.5.5.3.3. South Africa dermatologicals market, by route of administration
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Rest of LAMEA dermatologicals market, by disease
7.5.5.4.2. Rest of LAMEA dermatologicals market, by type
7.5.5.4.3. Rest of LAMEA dermatologicals market, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. ABBVIE INC. (ALLERGAN PLC)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. AMGEN INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GALDERMA
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments
8.4. GLAXOSMITHKLINE PLC. (GSK)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. JOHNSON & JOHNSON SERVICES, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. LEO PHARMA A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. ORGANON & CO. (MERCK)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. PFIZER INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. DERMATOLOGICALS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 02. DERMATOLOGICALS MARKET FOR ACNE, BY REGION, 2020–2030 ($MILLION)
TABLE 03. DERMATOLOGICALS MARKET FOR DERMATITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 04. DERMATOLOGICALSMARKET FOR PSORIASIS , BY REGION, 2020–2030 ($MILLION)
TABLE 05. DERMATOLOGICALSMARKET FOR SKIN CANCER, BY REGION, 2020–2030 ($MILLION)
TABLE 06. DERMATOLOGICALSMARKET FOR ROSACEA, BY REGION, 2020–2030 ($MILLION)
TABLE 07. DERMATOLOGICALSMARKET FOR ALOPECIA, BY REGION, 2020–2030 ($MILLION)
TABLE 08. DERMATOLOGICALSMARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 09. DERMATOLOGICALS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 10. DERMATOLOGICALSMARKET FOR PRESCRIPTION-BASED DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 11. DERMATOLOGICALSMARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 12. DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 13. DERMATOLOGICALSMARKET FOR TOPICAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 14. DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION , BY REGION, 2020–2030 ($MILLION)
TABLE 15. DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 16. DERMATOLOGICALS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 20. NORTH AMERICA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21. U.S. DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 22. U.S. DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 23. U.S. DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 24. CANADA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 25. CANADA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 26. CANADA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 27. MEXICO DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 28. MEXICO DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29. MEXICO DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 30. EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 31. EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32. EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 33. EUROPE DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34. GERMANY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 35. GERMANY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 36. GERMANY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 37. FRANCE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 38. FRANCE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 39. FRANCE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 40. UK DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 41. UK DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 42. UK DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 43. ITALY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 44. ITALY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 45. ITALY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 46. SPAIN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 47. SPAIN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 48. SPAIN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 49. REST OF EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 50. REST OF EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51. REST OF EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 53. ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54. ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 55. ASIA-PACIFIC DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56. JAPAN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 57. JAPAN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 58. JAPAN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 59. CHINA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 60. CHINA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 61. CHINA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 62. AUSTRALIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 63. AUSTRALIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64. AUSTRALIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 65. INDIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 66. INDIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 67. INDIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 68. SOUTH KOREA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 69. SOUTH KOREA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 70. SOUTH KOREA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 74. LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 75. LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76. LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 77. LAMEA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78. BRAZIL DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 79. BRAZIL DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 80. BRAZIL DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 81. SAUDI ARABIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 82. SAUDI ARABIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 83. SAUDI ARABIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 84. SOUTH AFRICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 85. SOUTH AFRICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 86. SOUTH AFRICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 87. REST OF LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 88. REST OF LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 89. REST OF LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 90. ABBVIE: COMPANY SNAPSHOT
TABLE 91. ABBVIE:OPERATING SEGMENT
TABLE 92. ABBVIE: PRODUCT PORTFOLIO
TABLE 93. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. AMGEN: COMPANY SNAPSHOT
TABLE 95. AMGEN:OPERATING SEGMENT
TABLE 96. AMGEN: PRODUCT PORTFOLIO
TABLE 97. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. GLADERMA: COMPANY SNAPSHOT
TABLE 99. GLADERMA:OPERATING SEGMENT
TABLE 100. GLADERMA: PRODUCT PORTFOLIO
TABLE 101. GLADERMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. GSK: COMPANY SNAPSHOT
TABLE 103. GSK: OPERATING SEGMENTS
TABLE 104. GSK: PRODUCT PORTFOLIO
TABLE 105. GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. J&J: COMPANY SNAPSHOT
TABLE 107. J&J: OPERATING BUSINESS SEGMENTS
TABLE 108. J&J: PRODUCT PORTFOLIO
TABLE 109. J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110. LEO PHARMA: COMPANY SNAPSHOT
TABLE 111. LEO PHARMA:OPERATING SEGMENT
TABLE 112. LEO PHARMA: PRODUCT PORTFOLIO
TABLE 113. LEO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. NOVARTIS: COMPANY SNAPSHOT
TABLE 115. NOVARTIS: OPERATING SEGMENT
TABLE 116. NOVARTIS: PRODUCT PORTFOLIO
TABLE 117. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118. ORGANON: COMPANY SNAPSHOT
TABLE 119. ORGANON: OPERATING SEGMENTS
TABLE 120. ORGANON: PRODUCT PORTFOLIO
TABLE 121. PFIZER: COMPANY SNAPSHOT
TABLE 122. PFIZER: OPERATING SEGMENTS
TABLE 123. PFIZER: PRODUCT PORTFOLIO
TABLE 124. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. SUN PHARMA: COMPANY SNAPSHOT
TABLE 126. SUN PHARMA: OPERATING SEGMENT
TABLE 127. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 128. SUN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
List of Figures
FIGURE 01. GLOBAL DERMATOLOGICALS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2019–2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2019–2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ACNE, BY COUNTRY, 2020–2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR DERMATITIS, BY COUNTRY, 2020–2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PSORIASIS, BY COUNTRY, 2020–2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR SKIN CANCER, BY COUNTRY, 2020–2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ROSACEA, BY COUNTRY, 2020–2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ALOPECIA, BY COUNTRY, 2020–2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2020–2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 23. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 24. COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY COUNTRY, 2020–2030 (%)
FIGURE 25. ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 26. ABBVIE: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 27. ABBVIE: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 28. AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 29. AMGEN: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 30. AMGEN: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 31. GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 32. GSK: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 33. GSK: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 34. J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 35. J&J: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 36. J&J: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 37. LEO PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 38. LEO PHARMA: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 39. LEO PHARMA: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 40. NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41. NOVARTIS: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 42. NOVARTIS: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 43. ORGANON: REVENUE, 2018–2020 ($MILLION)
FIGURE 44. ORGANON: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 45. ORGANON: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 46. PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 47. PFIZER: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 48. PFIZER: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 49. SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 50. SUN PHARMA: REVENU.S.ARE, BY SEGMENT, 2020 (%)
FIGURE 51. SUN PHARMA: REVENU.S.ARE, BY REGION, 2020 (%)

Companies Mentioned

  • AbbVie Inc.(Allergan PLC).
  • Amgen Inc.
  • Galderma
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Services Inc
  • Leo Pharma A/S
  • Novartis AG
  • Organon & Co (Merck)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...